Dr Michael Rosenblatt joins Merck & Co
This article was originally published in Scrip
Dr Michael Rosenblatt has been named executive vice-president and chief medical officer at Merck & Co. He will report directly to Merck's chairman, president and CEO, Richard Clark, will serve on the company’s executive committee and will oversee the company's global centre for scientific affairs. Dr Rosenblatt has served as dean of Tufts University School of Medicine since 2003. Before that, he was George R Minot Professor of Medicine at Harvard Medical School and chief of the division of bone and mineral metabolism research at Beth Israel Deaconess Medical Center.
You may also be interested in...
Flagship Ventures has recruited former Merck Chief Medical Officer Michael Rosenblatt as its CMO to mentor biopharma startups in the venture firm's portfolio – a hire that appears to be the first of its kind.
Mylan and Lupin have revealed when they expect to launch their etanercept biosimilar, Nepexto, in Europe after receiving formal European Commission approval.
The sellers of the anti-aging “cure-all” reached an agreement with the FTC in February that prohibits them from making false and unsubstantiated health claims and requires them to pay $660,000 in total to the Commission. Refund checks now are being issued to more than 1,300 defrauded consumers.